标题:
Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis
讲者:
刘丹
单位:
天津医科大学总医院
播放:
1117
论文摘要:
Objective: We performed this meta-analysis to determine the diagnose accuracy of procalcitonin to predict mortality in patients suffering different pathogenic features and disease severities.
Methods: We systematically searched the PubMed, Embase, Web of Knowledge and Cochrane databases. The diagnostic value of procalcitonin in predicting prognosis was determined using a bivariate meta-analysis model. We used the Q-test and I2 index to test heterogeneity.
Results: A total of 21 studies with a total of 6007 patients were included. Elevated procalcitonin level was a risk factor for death in community-acquired pneumonia (CAP) (RR 4.38, 95% CI 2.98-6.43), particularly in patients with a low CURB-65 score. The commonly used cut-off, 0.5ng/ml, had low sensitivity and was not able to identify patients at high risk of dying. With a cut-off of < 0.5 ng/ml, the pooled sensitivity and specificity of procalcitonin to predict death in CAP were 0.80 (95% CI: 0.66–0.89) and 0.67 (95% CI: 0.42–0.86), respectively. The overall area under the SROC curve was 0.82 (95% CI, 0.78–0.85), indicating a superior prognostic performance than the overall AUC of 0.76 (95% CI, 0.73–0.80). Furthermore, the procalcitonin assay with a functional sensitivity < 0.1 ng/ml was necessary to predict mortality in CAP clinically. For critically ill patients, an elevated procalcitonin level was associated with an increased risk of mortality (RR 4.18, 95% CI 3.19-5.48). The prognostic performance was almost equally restricted to patients suffering from VAP and CAP.
Conclusion: The commonly used cut-off, 0.5ng/ml, had low sensitivity and was not able to identify patients at high risk of dying. Further studies should assess whether a lower PCT threshold and more sensitive PCT assays can provide superior prognostic value for patients with pneumonia.